The market is changing: Can CMOs change with it?

With a shift towards smaller batch sizes, RTU needs more automation, standardization, and prevalidation.

With a shift towards smaller batch sizes, RTU needs more automation, standardization, and prevalidation.

The shift from blockbuster drugs to more targeted biologics has left contract manufacturers struggling to adapt. The smaller batch sizes for biologics, gene therapies, and personalized medicines require a different strategy if manufacturers are going to maintain their efficiency and keep costs under control. One option they’re exploring is ready-to use (RTU) packaging.

But, while RTU can enable more flexible filling, that alone will only add so much flexibility. In a world with more than 200 biologics on the market, and thousands more in various stages of the development pipeline, manufacturers looking to implement RTU will have to take it a step further. RTU needs more automation, standardization, and pre-validation.

Pharmaceutical filling lines at many companies were built with blockbuster drugs in mind, suited to drug runs in the millions rather than the tens of thousands. By enhancing RTU with these three key initiatives, contract manufacturers can reduce downtime, keep costs under control, and allow for more flexibility and faster changeovers on large lines.

Read the full article here.
As seen in Pharmaceutical Processing, April/May 2018, Advantage Business Media.

August 23, 2018

Contact

Chris Cassidy
Pharmaceutical Systems
SCHOTT North America, Inc.

top